These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20881215)

  • 1. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
    Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probabilistic risk analysis: improving early drug development decision making.
    Mudd PN; Groenendaal H; Bush MA; Schmith VD
    Clin Pharmacol Ther; 2010 Dec; 88(6):871-5. PubMed ID: 20944562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concepts and challenges in quantitative pharmacology and model-based drug development.
    Zhang L; Pfister M; Meibohm B
    AAPS J; 2008 Dec; 10(4):552-9. PubMed ID: 19003542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Zealand's drug development industry--strengths and opportunities.
    Lockhart MM; Babar ZU; Garg S
    N Z Med J; 2010 Jun; 123(1317):52-8. PubMed ID: 20657631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of strengths, weaknesses, opportunities, and threats in the development of a health technology assessment program in Turkey.
    Kahveci R; Meads C
    Int J Technol Assess Health Care; 2008; 24(2):235-40. PubMed ID: 18400128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
    Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
    Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic analysis of influenza vaccine shortage policies.
    Uscher-Pines L; Barnett DJ; Sapsin JW; Bishai DM; Balicer RD
    Public Health; 2008 Feb; 122(2):183-91. PubMed ID: 17825858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current role of model-based drug development.
    Suryawanshi S; Zhang L; Pfister M; Meibohm B
    Expert Opin Drug Discov; 2010 Apr; 5(4):311-21. PubMed ID: 22823084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental metabolomics: a SWOT analysis (strengths, weaknesses, opportunities, and threats).
    Miller MG
    J Proteome Res; 2007 Feb; 6(2):540-5. PubMed ID: 17269710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.